Dyne Therapeutics Revenue and Competitors

Boston, MA USA

Location

$333M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Dyne Therapeutics's estimated annual revenue is currently $17.5M per year.(i)
  • Dyne Therapeutics's estimated revenue per employee is $119,150
  • Dyne Therapeutics's total funding is $333M.
  • Dyne Therapeutics's current valuation is $478.7M. (January 2022)

Employee Data

  • Dyne Therapeutics has 147 Employees.(i)
  • Dyne Therapeutics grew their employee count by 34% last year.

Dyne Therapeutics's People

NameTitleEmail/Phone
1
President & CEOReveal Email/Phone
2
President & CEOReveal Email/Phone
3
VP, Head Translational BiomarkersReveal Email/Phone
4
VP, Head BiometricsReveal Email/Phone
5
VP - Head Platform DevelopmentReveal Email/Phone
6
VP, Head TechnologyReveal Email/Phone
7
SVP, PharmacovigilanceReveal Email/Phone
8
VP, Program Team Leader and Head New Product PlanningReveal Email/Phone
9
VP, Global Head Patient Advocacy and EngagementReveal Email/Phone
10
SVP, Program Team Leader and Head Program Management and OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Dyne Therapeutics?

Dyne was founded with a singular focus: to transform the lives of people with serious muscle diseases by pioneering muscle-targeted therapies. Our proprietary technologies provide the foundation for breakthrough treatments. We have assembled a world-class team of experts who are united by their commitment to fulfill this mission.

keywords:N/A

$333M

Total Funding

147

Number of Employees

$17.5M

Revenue (est)

34%

Employee Growth %

$478.7M

Valuation

N/A

Accelerator

Dyne Therapeutics News

2022-04-17 - Reviewing Dyne Therapeutics (NASDAQ:DYN) and Sol-Gel ...

Reviewing Dyne Therapeutics (NASDAQ:DYN) and Sol-Gel Technologies (NASDAQ:SLGL). Posted by admin on Apr 23rd, 2022.

2022-04-13 - -$0.88 EPS Expected for Dyne Therapeutics, Inc. (NYSE:DYN ...

Dyne Therapeutics posted earnings per share of ($0.50) in the same quarter last year, which suggests a negative year over year growth rate of 76...

2022-04-13 - -$0.88 Earnings Per Share Expected for Dyne Therapeutics ...

Analysts predict that Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Rating) will post ($0.88) earnings per share (EPS) for the current quarter,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$18.9M14723%$137.5M
#2
$28.7M148-10%$227M
#3
$28.9M14918%$125.4M
#4
$34.4M1490%N/A
#5
$23.9M1508%N/A